News from ABBVIE A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 11, 2016, 09:00 ET

AbbVie Launches Scholarship to Support Students Living with Rheumatologic Diseases

 AbbVie, a global biopharmaceutical company, announced the launch of the AbbVie Rheumatology Scholarship, designed to provide financial support...

Feb 10, 2016, 06:55 ET

AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis

AbbVie (NYSE:ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced positive top-line results from the second of two...

Jan 29, 2016, 07:47 ET

AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results

 AbbVie (NYSE: ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2015. "AbbVie delivered strong...

Jan 28, 2016, 06:55 ET

AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids

 AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of the first of two...

Jan 28, 2016, 00:59 ET

Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy

AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough...

Jan 21, 2016, 08:30 ET

MD Anderson, AbbVie Connect to Advance Cancer Immunotherapy

 The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie (NYSE: ABBV)...

Jan 20, 2016, 08:30 ET

AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

 AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough...

Jan 12, 2016, 08:30 ET

U.S. and European Regulators Accept Applications for AbbVie's Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted AbbVie's New...

Jan 11, 2016, 07:00 ET

AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the...

Jan 08, 2016, 09:00 ET

AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the start of a large Phase 3 clinical trial program to study the use...

Jan 07, 2016, 16:20 ET

AbbVie to Host Fourth-Quarter and Full-Year 2015 Earnings Conference Call

 AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2015 financial results on Friday, Jan. 29, 2016, before the market...

Dec 16, 2015, 08:05 ET

AbbVie to Present at the 34th Annual J.P. Morgan Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016. Richard A. Gonzalez,...

Dec 07, 2015, 08:30 ET

IMBRUVICA® (Ibrutinib) Phase 3 RAY Data Show Significant Reductions in Disease Progression versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients

 Today AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced results from the Phase 3 RAY (MCL3001) trial, which showed...

Dec 07, 2015, 07:15 ET

Combination Ibrutinib (IMBRUVICA®) Demonstrates a Strong Response Rate in Treatment-Naive Patients with Follicular Lymphoma

 Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced Phase 2 data demonstrated that the combination of ibrutinib...

Dec 06, 2015, 17:30 ET

Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma

 Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial...

Dec 06, 2015, 12:00 ET

AbbVie Announces New England Journal of Medicine Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal of...

Dec 06, 2015, 11:05 ET

AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational...

Dec 06, 2015, 11:00 ET

Ibrutinib (IMBRUVICA®) Improves Survival in Treatment-Naive Chronic Lymphocytic Leukemia Patients in the Phase 3 RESONATE™-2 Trial

 Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical...

Dec 04, 2015, 08:00 ET

AbbVie Launches Crohn's & Colitis Scholarship to Support Students Living with Inflammatory Bowel Disease

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the launch of the AbbVie Crohn's & Colitis Scholarship, designed to...